Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 14/20 | 0.56 |
| ▸ | FYN | P06241 | 4/20 | 0.56 |
| ▸ | CHUK | O15111 | 2/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1202618 | 0.89 | FYN (0.61) | IKBKBFYNCHUKMAPK10CDK2 | |
| SCHEMBL1203671 | 0.87 | FYN (0.55) | IKBKBFYNCHUKMAPK10RXFP1 | |
| SCHEMBL1203998 | 0.87 | FYN (0.57) | IKBKBFYNCHUKMAPK10 | |
| SCHEMBL1203077 | 0.86 | FYN (0.55) | IKBKBFYNCHUKMAPK10CDK2 | |
| SCHEMBL1203807 | 0.85 | IKBKB (0.57) | IKBKBFYNCHUKMAPK10CDK2 | |
| SCHEMBL1202657 | 0.85 | FYN (0.72) | IKBKBFYNCHUKMAPK10CDK2 | |
| SCHEMBL1202134 | 0.83 | IKBKB (0.65) | IKBKBFYNCHUKMAPK10CDK2 | |
| SCHEMBL1203467 | 0.82 | IKBKB (0.76) | IKBKBFYNCHUKMAPK10CDK2 | |
| SCHEMBL1202561 | 0.82 | IKBKB (0.58) | IKBKBFYNCHUKMAPK10CDK2 | |
| SCHEMBL1203005 | 0.82 | IKBKB (0.62) | IKBKBFYNCHUKMAPK10CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046127-A1 | Imidazopyridazines for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | IKBKB 297/4885FYN 403/4885CHUK 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.